Clairyon
Clairyon is a healthcare technology company that provides multimodal AI-powered clinical intelligence solutions. Their platform, Clairyon, helps healthcare providers improve patient care and outcomes by delivering real-time information to predict adverse events and enable targeted interventions. Key features include AI surveillance tools for sepsis prediction, GenAI for automating hospital quality reporting, and clinical decision support. Clairyon has demonstrated success with metrics like reducing sepsis mortality by 17% and improving SEP-1 compliance by 10%, and has monitored over 62 care units and helped more than 200,000 patients. They are HIPAA compliant and SOC 2 Type II compliant.
Clairyon
Clairyon is a healthcare technology company that provides multimodal AI-powered clinical intelligence solutions. Their platform, Clairyon, helps healthcare providers improve patient care and outcomes by delivering real-time information to predict adverse events and enable targeted interventions. Key features include AI surveillance tools for sepsis prediction, GenAI for automating hospital quality reporting, and clinical decision support. Clairyon has demonstrated success with metrics like reducing sepsis mortality by 17% and improving SEP-1 compliance by 10%, and has monitored over 62 care units and helped more than 200,000 patients. They are HIPAA compliant and SOC 2 Type II compliant.
TL;DR
Sector: Healthcare AI / Clinical intelligence
Headquarters / Founded: Founded 2021
Core products: Real-time predictive analytics (SEPS.IO), pediatric support (KIDMATCH), GenAI quality automation (QuaLLM)
Impact metrics: 62+ care units monitored; 200,000+ patients helped
Compliance: HIPAA and SOC 2 Type II
Recent funding: Grant from National Institute of Allergy and Infectious Diseases (Jun 24, 2024)
Company Overview
Problem Domain
Clinical surveillance, early warning for adverse events, and automated quality abstraction/reporting in hospital settings.
Founded
2021
Industry
Data and Analytics
Tech Stack
Funding Track Record
1000000
Investor Signal
“National Institute of Allergy and Infectious Diseases”